Virazole, Rebetol(ribavirin)
Cotronak, Rebetol, Ribavirin, Virazole (ribavirin) is a small molecule pharmaceutical. Ribavirin was first approved as Virazole on 1985-12-31. It is used to treat chronic hepatitis c, human adenovirus infections, respiratory syncytial virus infections, virus diseases, and west nile fever in the USA. It has been approved in Europe to treat chronic hepatitis c. The pharmaceutical is active against inosine-5'-monophosphate dehydrogenase 2 and inosine-5'-monophosphate dehydrogenase 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Ribavirin (discontinued: Copegus, Rebetol, Ribasphere, Ribavirin, Virazole)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Ribavirin
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| VIRAZOLE | Bausch Health Companies | N-018859 DISCN | 1985-12-31 | 1 products, RLD |
| REBETOL | Merck & Co | N-020903 DISCN | 1998-06-03 | 2 products |
| COPEGUS | Roche | N-021511 DISCN | 2002-12-03 | 2 products, RLD |
| REBETOL | Merck & Co | N-021546 DISCN | 2003-07-29 | 1 products, RLD |
Hide discontinued
Indications
FDA
EMA
Show 17 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
1118 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic hepatitis c | D019698 | EFO_0004220 | B18.2 | 2 | 23 | 18 | 36 | 24 | 103 |
| Hepatitis c | D006526 | — | B19.2 | 2 | 16 | 22 | 39 | 24 | 102 |
| Hepatitis | D006505 | — | K75.9 | 1 | 15 | 20 | 37 | 23 | 96 |
| Hepatitis a | D006506 | EFO_0007305 | B15 | 1 | 14 | 18 | 36 | 23 | 92 |
| Chronic hepatitis | D006521 | — | K73.9 | — | 2 | 7 | 6 | 3 | 18 |
| Hiv infections | D015658 | EFO_0000764 | B20 | — | 2 | 6 | 1 | 1 | 10 |
| Coinfection | D060085 | — | — | — | — | 2 | 1 | 1 | 4 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | — | — | — | 1 | 1 | 2 |
| Anemia | D000740 | EFO_0004272 | D64.9 | — | — | — | 1 | — | 1 |
| Liver transplantation | D016031 | EFO_0010682 | — | — | — | — | 1 | — | 1 |
Show 5 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infections | D007239 | EFO_0000544 | — | — | 2 | 2 | — | — | 4 |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | — | 2 | — | 2 | 4 |
| Chronic hepatitis b | D019694 | EFO_0004239 | B18.1 | — | — | 3 | — | — | 3 |
| Hepatitis b | D006509 | — | — | — | — | 1 | — | 1 | 2 |
| Communicable diseases | D003141 | — | — | — | 1 | 1 | — | — | 2 |
| Recurrence | D012008 | — | — | — | — | 1 | — | — | 1 |
| Fibrosis | D005355 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 3 | 1 | — | — | — | 3 |
| Treatment failure | D017211 | — | — | — | 1 | — | — | — | 1 |
| Depression | D003863 | — | F33.9 | — | 1 | — | — | — | 1 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | 1 | — | — | — | 1 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | — | 1 | — | — | — | 1 |
| Chronic hepatitis d | D019701 | — | — | — | 1 | — | — | — | 1 |
| Hepatitis d | D003699 | EFO_0007304 | — | — | 1 | — | — | — | 1 |
| Hepacivirus | D016174 | — | — | 1 | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv | D006678 | — | O98.7 | — | — | — | — | 1 | 1 |
| Insulin resistance | D007333 | EFO_0002614 | E88.819 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Ribavirin |
| INN | ribavirin |
| Description | Ribavirin is a white powder and exists in two polymorphic forms. Ribavirin is a 1-ribosyltriazole that is the 1-ribofuranosyl derivative of 1,2,4-triazole-3-carboxamide. A synthetic guanosine analogue, it is an inhibitor of HCV polymerase and possesses a broad spectrum of activity against DNA and RNA viruses. It has a role as an antimetabolite, an antiviral agent, an antiinfective agent and an EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor. It is a 1-ribosyltriazole, an aromatic amide and a monocarboxylic acid amide. Ribavirin is a synthetic nucleoside analog of ribofuranose with activity against hepatitis C virus and other RNA viruses. Ribavirin is incorporated into viral RNA, thereby inhibiting viral RNA synthesis, inducing viral genome mutations, and inhibiting normal viral replication. |
| Classification | Small molecule |
| Drug class | antivirals |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1 |
Identifiers
| PDB | — |
| CAS-ID | 36791-04-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1643 |
| ChEBI ID | 63580 |
| PubChem CID | 37542 |
| DrugBank | DB00811 |
| UNII ID | 49717AWG6K (ChemIDplus, GSRS) |
Target
Agency Approved
IMPDH1
IMPDH1
Organism
Homo sapiens
Gene name
IMPDH1
Gene synonyms
IMPD1
NCBI Gene ID
Protein name
inosine-5'-monophosphate dehydrogenase 1
Protein synonyms
IMP (inosine 5'-monophosphate) dehydrogenase 1, IMP (inosine monophosphate) dehydrogenase 1, IMPD 1, IMPDH 1, IMPDH-I
Uniprot ID
Mouse ortholog
Impdh1 (23917)
inosine-5'-monophosphate dehydrogenase 1 (P50096)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Ribavirin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 37,350 documents
View more details
Safety
Black-box Warning
Black-box warning for: Ribavirin, Virazole
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
95,748 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use